pharmaphorum

JANUARY 3, 2023

Side-effect data from the open-label studies was also encouraging, helping to downplay concerns abut evenamide’s cardiovascular and central nervous system safety that emerged in 2019. ” The new data could accelerate partnering efforts of the drug this year.

Side effects 104

Side effects Biopharma Patients Competition 104

Pharmaceutical Technology

JANUARY 27, 2023

Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017). All three treatments are monoclonal antibodies. Some 48% of patients on Briumvi also suffered with infusion reactions.

Marketing 52

Marketing Side effects Safety Patients 52

Pharmaceutical Technology

APRIL 24, 2023

The combination therapy also caused fewer side effects, with heart problems and hypertension as the most common ones, based on the final draft guidance. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

Food and Drug Administration 52

Food and Drug Administration Side effects Sales Food 52

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6

Engineering 52

Engineering Side effects Competition Sales 52

Contrarian Sales Techniques

FEBRUARY 26, 2023

The paper was presented at the International Conference on Pharmaceutical Research and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017. I understand that in developing countries, citizens can usually trust that the medicines on pharmacy shelves are safe, authentic, and effective.

Pharmaceutical 52

Pharmaceutical Medicine Government Manufacturing 52

Pharmaceutical Technology

NOVEMBER 30, 2022

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%

Medical 98

Medical Manufacturing Insurance Side effects 98